Antoine Decrulle

USPTO Granted Patents = 24 (Patent Applications = 9)

EPO Patents = 1 (Patent Applications = 10)

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2020-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12460216 - Phage-derived particles for in situ delivery of DNA payload into C. acnes population (2025-11-04),

2. 12454696 - recombinant phages encoding a human protein (2025-10-28),

3. 12214070 - Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins (2025-02-04),

4. 11970701 - Phage-derived particles for in situ delivery of DNA payload intopopulation (2024-04-30),

5. 11952595 - Production of lytic phages (2024-04-09),

6. 11952594 - Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof (2024-04-09),

7. 11946056 - Optimized vector for delivery in microbial populations (2024-04-02),

8. 11939598 - Production bacterial cells and use thereof in production methods (2024-03-26),

9. 11905516 - Optimized vector for delivery in microbial populations (2024-02-20),

10. 11840695 - Recombinantphages comprising transgenes (2023-12-12),

11. 11839645 - Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins (2023-12-12),

12. 11820989 - Phage-derived particles for in situ delivery of DNA payload intopopulation (2023-11-21),

13. 11739304 - Production of lytic phages (2023-08-29),

14. 11697802 - Production bacterial cells and use thereof in production methods (2023-07-11),

15. 11690880 - Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders (2023-07-04),

Title: The Innovative Contributions of Antoine Decrulle: A Pioneer in Biotechnological Patents

Introduction: Antoine Decrulle, an esteemed inventor based in Paris, France, has made notable strides in the field of biotechnology, with an impressive portfolio of 22 patents. His groundbreaking inventions focus on the application of engineered postbiotics and phage-derived particles for innovative cosmetic and genetic applications.

Latest Patents: Among his latest inventions, Decrulle's patent titled "Cosmetic Use of Engineered Postbiotics Comprising Bacteriocins and/or Endolysins" outlines a method for cosmetic skin or mucosal care. This method involves the application of a postbiotic composition that includes at least one postbiotic and one bacteriocin and/or endolysin, which synergistically work together to enhance cosmetic effects. Another significant patent is "Phage-Derived Particles for In Situ Delivery of DNA Payload into Population." This invention concerns the use of DNA vectors equipped with a phage packaging signal and a gene of interest to produce phage-derived particles capable of effectively transducing recipient cells for transgene expression.

Career Highlights: Decrulle has distinguished himself in the biotech sphere through his association with prominent institutions including Eligo Bioscience and Institut Pasteur. His work at these organizations has contributed significantly to the advancement of biotechnological research and innovation.

Collaborations: Throughout his career, Antoine Decrulle has collaborated with notable figures such as Xavier Duportet and Jesus Fernandez Rodriguez. These partnerships have enhanced his research and innovations, leading to the development of impactful biotechnological solutions.

Conclusion: Antoine Decrulle stands out as a trailblazer in the realm of biotechnology, with his patented inventions reflecting his commitment to innovation. His advancements in the aesthetic and genetic applications of postbiotics and phage-derived particles not only exemplify his expertise but also hold promising potential for future developments in these fields.

This text is generated by artificial intelligence and may not be accurate.